394735-18-3

Basic information

• Product Name: [1-(CyclobutylMethyl)-2-(MethoxyMethylaMino)-2-oxoethyl]-carbaMic Acid 1,1-DiMethylethyl Ester
• Synonyms: [1-(CyclobutylMethyl)-2-(MethoxyMethylaMino)-2-oxoethyl]-carbaMic Acid 1,1-DiMethylethyl Ester;N-[1-(CyclobutylMethyl)-2-(MethoxyMethylaMino)-2-oxoethyl]-carbaMic Acid 1,1-DiMethylethyl Ester
• CAS NO: 394735-18-3
• Molecular Formula: C₁₄H₂₆N₂O₄
• Molecular Weight: 286.36724
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 394735-18-3.mol
• Article Data: 20

Chemical Properties

• Appearance: /
• Solubility: Dichloromethane, Ethyl Acetate, Methanol
• CAS DataBase Reference: [1-(CyclobutylMethyl)-2-(MethoxyMethylaMino)-2-oxoethyl]-carbaMic Acid 1,1-DiMethylethyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(CyclobutylMethyl)-2-(MethoxyMethylaMino)-2-oxoethyl]-carbaMic Acid 1,1-DiMethylethyl Ester(394735-18-3)
• EPA Substance Registry System: [1-(CyclobutylMethyl)-2-(MethoxyMethylaMino)-2-oxoethyl]-carbaMic Acid 1,1-DiMethylethyl Ester(394735-18-3)

Safety Data

• Hazardous Substances Data: 394735-18-3(Hazardous Substances Data)

Usage

Description

[1-(CyclobutylMethyl)-2-(MethoxyMethylaMino)-2-oxoethyl]-carbaMic Acid 1,1-DiMethylethyl Ester is a white solid compound with a complex chemical structure. It is characterized by its cyclobutylmethyl and methoxymethylamino groups, which contribute to its unique properties and potential applications.

Uses

Used in Pharmaceutical Industry:
[1-(CyclobutylMethyl)-2-(MethoxyMethylaMino)-2-oxoethyl]-carbaMic Acid 1,1-DiMethylethyl Ester is used as a key intermediate in the synthesis of hepatitis C virus (HCV) NS3 serine protease inhibitors. These inhibitors play a crucial role in the development of antiviral drugs targeting HCV, as they help to block the replication of the virus and prevent the progression of the disease.
Used in Chemical Research:
As a complex organic molecule, [1-(CyclobutylMethyl)-2-(MethoxyMethylaMino)-2-oxoethyl]-carbaMic Acid 1,1-DiMethylethyl Ester may also be utilized in various chemical research applications. Its unique structure and properties can be explored for potential use in the development of new materials, catalysts, or other chemical compounds with specific functions.
Used in Drug Development:
[1-(CyclobutylMethyl)-2-(MethoxyMethylaMino)-2-oxoethyl]-carbaMic Acid 1,1-DiMethylethyl Ester's potential applications extend to the field of drug development, where it may be used as a starting material or a building block for the creation of novel therapeutic agents. Its structural features could be exploited to design new drugs with improved efficacy, selectivity, and safety profiles for the treatment of various diseases and conditions.

Upstream product

• 17247-58-4 (Bromomethyl)cyclobutane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1025799-39-6 2-(benzhydrylidene-amino)-3-cyclobutyl-propionic acid ethyl ester 
• 816430-02-1 ethyl 2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoate 
• 394735-17-2 ethyl 2-amino-3-cyclobutylpropanoate 
• 565456-75-9 2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 394735-25-2 {(S)-2-[(1R,2S,5S)-2-(2-Carbamoyl-1-cyclobutylmethyl-2-hydroxy-ethylcarbamoyl)-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxo-ethyl}-carbamic acid tert-butyl ester 
• 394735-28-5 (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicylo[3.1.0]-hexane-2-carboxamide 
• 1036931-36-8 3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride 
• 394735-22-9 tert-butyl 4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-ylcarbamate 
• 394730-60-0 boceprevir 
• 394735-20-7 (2-cyano-1-cyclobutylmethyl-2-hydroxyethyl)carbamic acid tert-butyl ester 
• 394735-19-4 (2-cyclobutyl-1-formylethyl)carbamic acid tert-butyl ester 

Relevant articles and documents

PROCESS FOR PREPARATION OF BOCEPREVIR AND INTERMEDIATES THEREOF

THE PRESENT INVENTION RELATES TO AN IMPROVED PROCESS FOR THE PREPARATION OF (1R,5S)-N-[3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL]-3-[2(S)-[[[(1,1-DIMETHYLETHYL)AMINO]CARBONYL] AMINO]-3,3-DIMETHYL-1-OXOBUTYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXAN-2(S)-CARBOXAMIDE AND ITS INTERMEDIATES

Pharmaceutical formulations and methods of treatment using the same

Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection

Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide. Currently the only therapeutic regimens are subcutaneous interferon-α or polyethylene glycol (PEG)-interferon-α alone or in combination with oral ribavirin. Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virological response. Herein, the SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clinical trials in human beings for the treatment of hepatitis C viral infections is described. X-ray structure of inhibitor 70 complexed with the NS3 protease and biological data are also discussed.